蚓激酶联合阿司匹林预防缺血性卒中复发的研究

The prophylactic effect of lumbrokinase plus aspirin on recurrence of ischemic stroke in the patients

目的:观察蚓激酶联合阿司匹林预防缺血性卒中复发的有效性及安全性。方法:87例康复期脑梗死患者分成对照组和治疗组,对照组单独服用肠溶阿司匹林75 mg/d,治疗组再加用蚓激酶180万单位/d,随访6个月,观察缺血性卒中的复发率及出血事件发生率,并于治疗30 d时进行神经功能缺损评分及临床疗效评价。结果:蚓激酶联用阿司匹林组缺血性卒中的复发率为4.4%,效果优于阿司匹林,后者单独使用的复发率为11.9%(P<0.05),联合使用不增加出血危险。蚓激酶与阿司匹林合用可显著改善患者神经功能,临床总有效率为86.7%,优于阿司匹林单独使用61.9%的有效率(P<0.05)。结论:蚓激酶联合阿司匹林能有效预防缺血性卒中复发,副作用较小、耐受性好。

AIM ： To assess the prophylactic effect of lumbrokinase plus aspirin on recurrence of ischemic stroke in the patients recovering from cerebral infarction. METHODS ： 87 patients of cerebral infarction were assigned to two groups：control and treatment group, treated respectively with aspirin in control group and lumbrokinase plus aspirin in the treatment group. The recurrence rate and clinical efficacy were analysed. RESULTS： There were remarkable differences in recurrence rate and clinical efficacy between the two groups （P 〈 0.05 ）. The recurrence rate was 11.9% in the control group and 4.4% in the treatment group. The total clinical efficacy was 61.9% and 86.7% respectively. No patients died. CONCLUSION： Lumbrokinase plus aspirin can be used for secondary prevention of ischemic stroke. It is safe and well-tolerated and may be of great clinical value.